HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Nov.10)-Biotech Model Validation, CNPGC Need to Fulfill Commitment to Taiji

Greatview Aseptic Packaging (468.HK) Update - Some New Information Worth the Attention

CPMC Holdings (906.HK) Privatization Update - ORG Is Pushing Baosteel to Raise Its Offer

CPMC Holdings (906.HK) Privatization Update - Will ORG Withdraw Midway?

Event-Driven

<ul>
<li>Since ORG needs to pay a high price, it certainly hopes that the effect of the acquisition is 1+1&gt;2, otherwise it is equivalent to failure considering the future debt payment.</li>
<li>We’re unsure if the situation on Zhang Wei's side will change. If afterwards integration falls short of expectations, ORG may “deliberately slow down the progress”, which is a risk point.</li>
<li>Considering the complexity of this deal, we recommend investors do more comprehensive and deeper thinking. Due to risks behind, we certainly hope to obtain higher returns (at least 20% annualized).</li>
</ul>


Since ORG needs to pay a high price, it certainly hopes that the effect of the acquisition is 1+1&gt;2, otherwise it is equivalent to failure considering the future debt payment.
We’re unsure if the situation on Zhang Wei's side will change. If afterwards integration falls short of expectations, ORG may “deliberately slow down the progress”, which is a risk point.
Considering the complexity of this deal, we recommend investors do more comprehensive and deeper thinking. Due to risks behind, we certainly hope to obtain higher returns (at least 20% annualized).


Shanghai Baosteel Packaging-A (601968 CH)

CPMC Holdings (906.HK) Update - These Are the Reasons Why We Find This Deal "Tricky"